title: Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
abstract: Concerns that the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.
authors.affiliation: *Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; and †Department of Pathology, Emory University, Atlanta, GA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Radzio
authors.forename: Krisztina
authors.initials: K
authors.lastname: Hanley
authors.forename: James
authors.initials: J
authors.lastname: Mitchell
authors.forename: Shanon
authors.initials: S
authors.lastname: Ellis
authors.forename: Frank
authors.initials: F
authors.lastname: Deyounks
authors.forename: Leecresia
authors.initials: L
authors.lastname: Jenkins
authors.forename: Walid
authors.initials: W
authors.lastname: Heneine
authors.forename: J Gerardo
authors.initials: JG
authors.lastname: García-Lerma
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D008254:Macaca nemestrina; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010757:Phosphorous Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C574165:9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine; D019380:Anti-HIV Agents; D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D010757:Phosphorous Acids; D003841:Deoxycytidine; D017258:Medroxyprogesterone Acetate; D000068679:Emtricitabine; D000225:Adenine